Highly promisingresults for the combination of IO and targeted therapies have already been reportedfor other solid malignancies, such as in ERBB2/HER-2 positive gastric cancer[ClinicalTrials.gov identifier: NCT02954536].52 Thus far, only pre-clinical data exist for dual targeting of the FGFreceptors and immune checkpoints. This evidence concerns the gene ERBB2 and gastric cancer.